Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SPEE3D is an Australian additive manufacturing company that specializes in high-speed metal 3D printing using its proprietary Cold Spray Additive Manufacturing (CSAM) technology. While the company primarily serves the defense and industrial sectors, it has developed a significant healthcare application through its ACTIVAT3D antimicrobial copper coating technology. This process allows for the rapid 3D printing of copper onto existing metal surfaces, such as hospital door handles and rails, and has been laboratory-proven to kill 96% of the SARS-CoV-2 virus within two hours. SPEE3D's platform enables on-demand production of metal components, addressing supply chain challenges in both industrial and medical environments. The company operates globally with headquarters in Melbourne and a significant presence in the United States, including a manufacturing facility in New Hampshire.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SPEE3D.